Intense lipid-lowering 'benefits elderly' after ACS

Secondary analysis of IMPROVE-IT trial could influence guidelines, authors say

Adding ezetimibe to intensive statin therapy following acute coronary syndrome provides greater benefits to elderly patients than those in lower age groups, a US study has found.

heart drugs

In a secondary analysis of the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study, researchers compared the effects of simvastatin-ezetimibe combination therapy versus simvastatin alone by age group in more than 18,000 participants (mean age 64).

The original IMPROVE-IT findings, published in 2015, demonstrated the